Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:10:54.826Z.
Calculation as of: 2026-10-06T14:10:54.826Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 533c4696450707580a389d0c8167e09da333cd728c1767827588ef029f48caf5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.34B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.23B
EBITDA Yield
6.91%
TTM Avg
3.73%
3Y Avg
2.86%
5Y Avg
4.37%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $1.33B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.34B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.37B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.23B | 6.91% | 3.73% | 2.86% | 4.37% |
| Kardigan, Inc. (KARD)vs › | $1.23B | N/A | N/A | N/A | N/A |
| MannKind Corporation (MNKD)vs › | $1.22B | 1.91% | 3.43% | 3.63% | 3.63% |
| Cronos Group Inc. (CRON)vs › | $1.22B | 3.60% | 5.34% | 5.34% | 5.34% |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 8.69% | 3.11% | 3.11% | 3.25% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
